「復必泰」開發商BioNTech(BNTX.US)加入新加坡BioPIPS聯盟
新加坡科技研究局(A*STAR)和新加坡經濟發展局(EDB)今早(18日)發表聯合公告,指全球免疫療法公司BioNTech(BNTX.US)加入新加坡生物製藥創新計劃(BioPIPS)聯盟,有助於加強當地生物製劑生產領域的生產力和可持續性。
現有的聯盟成員包括全球製藥公司葛蘭素史克(GSK)和賽諾菲(Sanofi),以及新加坡的研究機構和高等教育機構如科研局、新加坡南洋理工大學(NTU)、新加坡國立大學(NUS)和新加坡理工大學(SIT)。
在新冠疫情大流行期間,由輝瑞/BioNTech聯合開發的「復必泰」新冠疫苗被多國採購,BioNTech聲名鵲起。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.